|
|
|
By Tom von Gunden, Chief Editor, Drug Delivery Leader | Chief Editor Tom von Gunden reports on innovations in oral delivery of drugs and biologics, including advances designed to increase permeability, solubility, and bioavailability, and to expand the types and sizes of therapeutic payloads. | |
|
|
Selecting Long-Acting Injectable Platforms For Complex Delivery Needs | By Amy C. Kauffman, Ph.D., Bristol Myers Squibb | Platform selection for long-acting injectables is increasingly complex because therapeutic modalities, delivery systems, and target product expectations have all diversified. Can your selected platform meet the needs of your product? |
|
|
|
|
|
|
| Designing Safer, Smarter Drug Delivery Devices Through Human Factors | Article | By Dr. Sylvine Raverdy-Wilson, BD Medical - Pharmaceutical Systems | Growing use of large‑volume subcutaneous therapies is increasing demand for wearable injectors that reduce user error, simplify preparation, and enhance safety through human‑factors‑focused design. |
|
|
| Advancing Lipid Nanoparticle Drug Delivery | White Paper | By Mahesh Karwa, Teresa Demuth, and Gaëlle Béalle, MilliporeSigma | Successfully scaling lipid nanoparticle drug delivery requires careful formulation, process development, and manufacturing strategies to support clinical progress and commercial readiness. |
|
|
| Bringing Drug Delivery Concepts To Commercial Reality | Article | By Bettine Boltres, West Pharmaceutical Services, Inc. | Turning a drug delivery concept into a market-ready product requires cross-functional expertise, guiding development from design and testing through manufacturing and launch. |
|
|
|
|
|
.png){kind=logo}
